Sunday, November 13, 2016
- 9:00AM-11:00AM
-
Abstract Number: 520
The HAQ Reversible and Irreversible Components Measuring Function in Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis- 9:00AM-11:00AM
-
Abstract Number: 497
The Identification of an ACR Score with the Optimal Discriminatory Ability Between Treatments in Patients with Early and Established Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis- 9:00AM-11:00AM
-
Abstract Number: 269
The Immunoproteasomes Are Essential for Maintaining Myokine Production and MHC Class I Expression in Idiopathic Inflammatory Myopathies
Muscle Biology, Myositis and Myopathies - Poster I: Basic/Translational- 9:00AM-11:00AM
-
Abstract Number: 18
The Impact of Disease-Related and Contextual Factors on Work Outcomes in Chronic Inflammatory Arthritis Patients Treated with Biologics: A Systematic Review
Epidemiology and Public Health - Poster I- 9:00AM-11:00AM
-
Abstract Number: 17
The Importance of Achieving Clinical Response to Treatment and Changes in Physical Ability and Quality of Life on Worker Productivity Outcomes in Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register
Epidemiology and Public Health - Poster I- 9:00AM-11:00AM
-
Abstract Number: 540
The Importance of Outcome Measures in Rheumatoid Arthritis – Validity of the Routine Assessment of Patient Index Data 3 in a Real World Setting
Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis- 9:00AM-11:00AM
-
Abstract Number: 395
The Influence of Early Achievement of “Clinically Inactive Disease” or “Minimal Disease Activity” on Long-Term Disability Outcomes in JIA
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster I: Juvenile Idiopathic Arthritis, Uveitis- 9:00AM-11:00AM
-
Abstract Number: 447
The Influence of Risk Presentation Format on Willingness to Start a Medication
Quality Measures and Quality of Care - ARHP Poster- 9:00AM-11:00AM
-
Abstract Number: 185
The Interferon Gene Signature Is Increased in Early DMARD Naive Rheumatoid Arthritis and Predicts a Poorer Response to Initial Therapy
Innate Immunity and Rheumatic Disease - Poster I- 9:00AM-11:00AM
-
Abstract Number: 791
The International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) Initiative – Update and Its Impact
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies- 9:00AM-11:00AM
-
Abstract Number: 654
The Level of B-Cell Active Cytokines and Soluble B-Cell Activating Factor/a Proliferation-Inducing Ligand Receptors in Patients with Primary Sjogren’s Syndrome
Sjögren's Syndrome - Poster I: Translational Science- 9:00AM-11:00AM
-
Abstract Number: 747
The Long-Term Outcomes on Leflunomide Treatment in Patients with Lupus Nephritis: A Twelve-Year Follow-up Study
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies- 9:00AM-11:00AM
-
Abstract Number: 505
The Longitudinal Stability of the RA Biomarkers RF and ACPA in Classifying RA Subtypes over Extended Follow up
Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis- 9:00AM-11:00AM
-
Abstract Number: 440
the Majority of Biologic Injectors Are Stored Under Suboptimal Conditions at Home
Quality Measures and Quality of Care - Poster I- 9:00AM-11:00AM
-
Abstract Number: 815
The Novel Anti-BICD2 Autoantibody Potentially Predicts a Favorable Disease Course in SSc